Progression of endocrine therapies for breast cancer: Where are we headed?

Expert Review of Anticancer Therapy

Volumn 7, Issue 11, 2007, Pages 1651-1664

  Arnedos, Monica ^a   Smith, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Endocrine; Therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; BUSERELIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FLUOROURACIL; FORMESTANE; FULVESTRANT; GEFITINIB; GESTAGEN; GONADORELIN; GOSERELIN; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE; TRASTUZUMAB; UNINDEXED DRUG; VOROZOLE;

ADJUVANT THERAPY; ARTHRALGIA; BONE DEMINERALIZATION; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; DYSPNEA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FATIGUE; FLUID RETENTION; FRAGILITY FRACTURE; GOLD STANDARD; GROWTH INHIBITION; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; INDIVIDUALIZATION; INHIBITION KINETICS; INJECTION SITE REACTION; JOINT STIFFNESS; LUNG EMBOLISM; MASTECTOMY; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OSTEOPOROSIS; OVARIECTOMY; PATIENT CARE; PERIPHERAL EDEMA; PREMENOPAUSE; PREOPERATIVE CARE; PROGNOSIS; PROTEIN CONFORMATION; RECEPTOR BINDING; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GROWTH; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 37349057484     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.11.1651     Document Type: Review

References (110)

1. Ries L, Harkins D, Krapcho M. Cancer SEER Statistics Review, 1975-2003. National Cancer Insititute, Bethesda, MD, USA (2006).
2. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J. Clin. Oncol. 21(1), 28-34 (2003).
3. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2, 104-107 (1896).
4. Rose C, Mouridsen HT. Treatment of advanced breast cancer with tamoxifen. Recent Results Cancer Res. 91, 230-242 (1984).
5. Mauri D, Pavlidis N, Polyzos NP et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J. Natl Cancer Inst. 98(18), 1285-1291 (2006).
6. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21(11), 2101-2109 (2003).
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
8. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl. J. Med. 339(22), 1609-1618 (1998).
9. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351(9114), 1451-1467 (1998).
10. Smith CL, O'Malley BW..Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25(1), 45-71 (2004).
11. Friedman ZY. Recent advances in understanding the molecular mechanisms of tamoxifen action. Cancer Invest. 16 (6), 391-396 (1998).
12. Fisher B, Costantino JP, Wickerharn DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90 (18), 1371-1388 (1998).
13. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated-with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (7), 637-645 (1999).
14. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 65 (2), 125-134 (2001).
15. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23). 2727-2741 (2006).
16. Simpson ER, Mahendroo MS, Means GD et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. 15(3), 342-355 (1994).
17. Cheung KL. Endocrine therapy for breast cancer: an overview. Breast 16(4), 327-343 (2007).
18. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3), 223-234 (2007).
19. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25(5), 4864-4892 (2007).
20. Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA. 17L). Ann. Oncol. 16 (5), 707-715 (2005).
21. Dowsett M, Jacobs S, Aherne J et al. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Clin. Ther. 14(Suppl. A), 97-103 (1992).
22. Nicholson RI, Walker KJ, Turkes A et al. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J. Steroid Bioechem. 23(5B), 843-847 (1985).
23. Taylor CW, Green S, Dalton WS et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J. Clin. Oncol. 16(3), 994-999 (1998).
24. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 106 (Pt 4), 1377-1388 (1993).
25. Howell A, DeFriend D, Robertson J et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345(8941), 29-30 (1995).
26. Watanabe T, Sano M, Ohno S et al. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study. Anticancer Res. 24(2C), 1275-1280 (2004).
27. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol. 22(9), 1605-1613 (2004).
28. Howell A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104(2), 236-239 (2005).
29. Ingle JN, Suman VJ, Rowland KM et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol. 24(7), 1052-1056 (2006).
30. Haller DG, Glick JH. Progestational agents in advanced breast cancer: an overview. Semin. Oncol. 13(Suppl. 4), 2-8 (1986).
31. Gregory EJ, Cohen SC, Oines DW et al. Megestrol acetate therapy for advanced breast cancer. J. Clin. Oncol. 3(2), 155-160 (1985).
32. Blossey HC, Wander HE, Koebberfing J et al. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer (Suppl. 6), 1208-1215 (1984)
33. Mattssn W. Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res. Treat. 3(2), 231-235 (1983).
34. Ingle JN, Ahmann DL, Green SJ et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am. J. Clin. Oncol. 5 (2), 155-160 (1982).
35. Carlini P, Bria E, Giannarelli D et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 104(7), 1335-1342 (2005).
36. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol. 18(22), 3748-3757 (2000).
37. Nabholtz JM, Bonneterre J, Buzdar A et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer39(12), 1684-1689 (2003).
38. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol. 18(22), 3758-3767 (2000).
39. Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, Phase III study. Am. J. Clin. Oncol. 26(3), 317-322 (2003).
40. Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20(3), 751-757 (2002).
41. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) a randomized Phase III trial of the EORTC Breast Group. J. Clin. Oncol. 14, 515 (2004) (Abstract).
42. Ingle JN, Krook JE, Green SJ et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J. Clin. Oncol. 4(2), 178-185 (1986).
43. Pritchard KI, Thomson DB, Myers RE et al. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat. Rep. 64(6-7), 787-796 (1980).
44. Sawka CA, Pritchard KI, Shelley W et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1. Breast Cancer Res. Treat. 44(3), 211-215 (1997).
45. Buchanan RB, Blamey RW, Durrant KR et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J. Clin. Oncol. 4(9), 1326-1330 (1986).
46. Boccardo F, Rubagotti A, Perrotta A et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann. Oncol. 5(4), 337-342 (1994).
47. Jonat W, Kaufmann M, Blamey RW et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur. J. Cancer 31A(2), 137-142 (1995).
48. Klijn JG, Beex LV, Mauiriac L et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 92(11), 903-911 (2000).
49. Klijn JG, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J. Clin. Oncol. 19(2), 343-353 (2001).
50. Forward DP, Cheung KL, Jackson L et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br. J. Cancer 90 (3), 590-594 (2004).
51. Celio L, Martinetti A, Ferrari L et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res. 19(3B), 2261-2268 (1999).
52. Carlson RW, Schurman CM, Rivera F et al. Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer. J. Clin. Oncol. 25(Suppl. 18), 1030 (2007) (Abstract).
53. Cheung KL, Winterbottom L, Owers R et al. Goserelin plus anastrozole as first-line endocrine therapy for premenopausal women with oestrogen receptor (ER) positive advanced breast cancer (ABC) J. Clin. Oncol. 23(Suppl. 16), 731 (2005) (Abstract).
54. Thurlimann B, Robertson JF, Nabholtz JM et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur. J. Cancer 39(16), 2310-2317 (2003).
55. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J. Clin. Oncol. 18(11), 2234-2244 (2000).
56. Bertelli G, Garrone O, Merlano, M et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69(6), 471-477 (2005).
57. Gradishar W, Chia S, Piccart M et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, Phase III trial in postmenopausal women with advanced breast cancer. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 12).
58. Mustacchi G, Ceccherini R, Milani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the Phase III randomized controlled multicenter GRETA trial. Ann. Oncol. 14(3), 414-420 (2003).
59. Fennessy M, Bates T, MacRae K et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br. J. Surg. 91 (6), 699-704 (2004).
60. Semiglazov VF, Semiglazov V, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer. J. Clin. Oncol. 22 (Suppl. 14), 519 (2004) (Abstract).
61. Semiglazov VF, Semiglazov VV, Ivanov VG et al. Preoperative hormonal therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients. Eur. J. Cancer 2(3), 71 (2004) (Abstract).
62. Dixon JM, Renshaw L, Bellamy C et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin. Cancer Res. 6(6), 2229-2235 (2000).
63. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12(11), 1527-1532 (2001).
64. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol. 19(18), 3808-3816 (2001).
65. Dowsett M, Ebbs SR, Dixon JM et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J. Clin. Oncol. 23(11), 2477-2492 (2005).
66. Dowsett M, A'Hern R, Smith I. Ki-67 after 2 weeks endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 46).
67. + breast cancer (T2N1-2, T3N0-1, T4N0M0). J. Clin. Oncol. 23(Suppl. 16), 530 (2005) (Abstract).
68. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23(22), 5108-5116 (2005).
69. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared with Tamoxifen (PROACT) trial. Cancer 106(10), 2095-2103 (2006).
70. Llombart A, Ruiz A, Lopez-Guerrero JA et al. Obejctive response to neoadjuvant letrozole predicts distant disease free survival in postmenopausal women with stage II-III ER/PgR-positive breast cancer. Ann. Oncol. 9(11), 252 (2006) (Abstract).
71. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women wiih early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324), 2131-2139 (2002).
72. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353(26), 2747-2757 (2005).
73. Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin. Cancer Res. 12 (3 Pt 2), S1037-S1048 (2006).
74. Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl Cancer Inst. 97(17), 1254-1261 (2005).
75. Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 23(30), 7512-7517 (2005).
76. Dowsett M, Allred D. On behalf of the TransATAC Investigators, relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 48).
77. Viale G, Regan M, Dell'Orto P et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 44).
78. Duffy S, Jackson TL, Lansdown M et al. The ATAC (Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum. Reprod. 21(2), 545-553 (2006).
79. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561), 559-570 (2007).
80. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 7(12), 991-996 (2006).
81. Boccardo, F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin. Oncol. 23(22), 5138-5147 (2005).
82. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484), 455-462 (2005).
83. Jakesz R, Gnant M, Greil R et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-year-analysis of ABCSG Trial 8. Presented at: The 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 13).
84. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14(10), 2738-2746 (1996).
85. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 93(9), 684-690 (2001).
86. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349 (19), 1793-1802 (2003).
87. Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a) J. Clin. Oncol. 23(Suppl. 16), 527 (2005) (Abstract).
88. Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J. Clin. Oncol. 24(16), 2444-2447 (2006).
89. Kendall A, Dowsett M, Folkerd E et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann. Oncol. 17(4), 584-587 (2006).
90. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).
91. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol. 24(33), 5305-5312 (2006).
92. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J. Clin. Oncol. 24(22), 3629-3635 (2006).
93. Cuzick J, Ambroisine L, Davidson N et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta- analysis of individual patient data from randomised adjuvant trials. Lancet 369(9574), 1711-1723 (2007).
94. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol. 20(24), 4628-4635 (2002).
95. Jakesz R, Hausmaninger H, Kubista E et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group trial 5. J. Clin. Oncol. 20(24), 4621-4627 (2002).
96. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99(2), 167-170 (2007).
97. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
98. van't Veer LJ, Dai H, van MJ de Vijver et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002).
99. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
100. Davidson NE, AM O'Neill, Vukov AM et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J. Clin. Oncol. 23(25), 5973-5982 (2005).
101. Davidson NE, A O'Neill, Vukov A et al. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group Phase III intergroup trial (E5188, INT-0101). J. Clin. Oncol. 22, 15 (2003).
102. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst. 96 (12), 926-935 (2004).
103. Nicholson RI, Hutcheson IR, Knowiden JM et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin. Cancer Res. 10(1 Pt 2), S346-S354 (2004).
104. + breast cancer (Study 223). J. Clin. Oncol. 24(Suppl. 18), 515 (2006) (Abstract).
105. Mackey JR, Kaufman B, Clemens M et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Presented at: The 29th Annual San Antonio breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract).
106. Chu I, Blackwell K, Chen S et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 65(1), 18-25 (2005).
107. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19(56), 6680-6686 (2000).
108. deGraffenried LA, Friedrichs WE, Russell DH et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin. Cancer Res. 10(23), 8059-8067 (2004).
109. Rudolf J, Boulay A, Zumstein-Mecker S et al. The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas. Proc. Am. Assoc. Cancer Res. 45, 5619 (2004) (Abstract).
110. Tabernero J, Rojo F, Burris H et al. A Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. J. Clin. Oncol. 23(Suppl. 16), 3007 (2005) (Abstract).